Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]
Fei Y, Xie Z, Luo Y, et al. Drug Des Devel Ther. 2025;19:3751–3761. Page 3760, first line, the text “Our current study had similar findings” should read “Our study observed an increase in the exposure to HRS-1780 with both mild and moderat...
Saved in:
| Main Authors: | Fei Y, Xie Z, Luo Y, Yong X, Li N, Huang R, Du X, Zhu Y, Lan D, Qi Y, Cheng G, Wang Q, Shen K |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-06-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/corrigendum-pharmacokinetics-and-safety-of-hrs-1780-in-renal-impaired--peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study
by: Fei Y, et al.
Published: (2025-05-01) -
Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01) -
Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment
by: Shengjie Zhang, et al.
Published: (2025-03-01) -
Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial
by: Subha V. Raman, et al.
Published: (2019-10-01) -
Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (CHF6001) Pharmacokinetics: Two Open‐Label, Parallel‐Group, Single‐Center Studies
by: Annalisa Piccinno, et al.
Published: (2025-05-01)